K02288 10 mg | 99.27%
TargetMol
K02288
Search Results
BAY 11-7082 5 mg | 97.91%
TargetMol
BAY 11-7082, a NF-κB inhibitor, inhibits TNFα-induced IκBα phosphorylation. BAY 11-7082 inhibits ubiquitin-specific protease USP7 and USP21.
More Information Supplier PageBAY 11-7082
BAY 11-7082 50 mg | 97.91%
TargetMol
BAY 11-7082, a NF-κB inhibitor, inhibits TNFα-induced IκBα phosphorylation. BAY 11-7082 inhibits ubiquitin-specific protease USP7 and USP21.
More Information Supplier PageBAY 11-7082
BAY 11-7082 10 mg | 97.91%
TargetMol
BAY 11-7082, a NF-κB inhibitor, inhibits TNFα-induced IκBα phosphorylation. BAY 11-7082 inhibits ubiquitin-specific protease USP7 and USP21.
More Information Supplier PageBAY 11-7082
BAY 11-7082 100 mg | 97.91%
TargetMol
BAY 11-7082, a NF-κB inhibitor, inhibits TNFα-induced IκBα phosphorylation. BAY 11-7082 inhibits ubiquitin-specific protease USP7 and USP21.
More Information Supplier PageBAY 11-7082
Des(benzylpyridyl) Atazanavi 5 mg | 98.00%
TargetMol
The N-dealkylated metabolite (M1) of Atazanavir, a HIV protease inhibitor.
More Information Supplier PageDes(benzylpyridyl) Atazanavi
K02288 50 mg | 99.27%
TargetMol
K02288
K02288 5 mg | 99.27%
TargetMol
K02288
YL-109 5 mg | 98.00%
TargetMol
YL-109, a novel anticancer agent, can inhibit breast Y cell growth and invasiveness in vitro and in vivo.
More Information Supplier PageYL-109
YL-109 10 mg | 98.00%
TargetMol
YL-109, a novel anticancer agent, can inhibit breast Y cell growth and invasiveness in vitro and in vivo.
More Information Supplier PageYL-109